|
|
|
MIRA INFORM REPORT
|
Report No. : |
487030 |
|
Report Date : |
20.01.2018 |
IDENTIFICATION DETAILS
|
Name : |
FLUXION BIOSCIENCES INC. |
|
|
|
|
Registered Office : |
Corporation Trust Center 1209 Orange St, Wilmington, New Castle, De,
19801 |
|
|
|
|
Country : |
United States |
|
|
|
|
Date of Incorporation : |
28.10.2005 |
|
|
|
|
Legal Form : |
Corporation |
|
|
|
|
Line of Business : |
Subject develops analytical instruments for functional cellular
analyses in life science, drug discovery, and diagnostic applications. |
|
|
|
|
No. of Employees : |
30 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd January
2017)
|
MIRA’s Rating : |
B |
|
Credit Rating |
Explanation |
Rating Comments |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Slow but Correct |
|
|
|
|
Litigation : |
Exist |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.06.2017) |
Current Rating (30.09.2017) |
|
United States |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
UNITED STATES - ECONOMIC OVERVIEW
The US has the most technologically powerful economy in the world, with a per capita GDP of $57,300. US firms are at or near the forefront in technological advances, especially in computers, pharmaceuticals, and medical, aerospace, and military equipment; however, their advantage has narrowed since the end of World War II. Based on a comparison of GDP measured at purchasing power parity conversion rates, the US economy in 2014, having stood as the largest in the world for more than a century, slipped into second place behind China, which has more than tripled the US growth rate for each year of the past four decades.
In the US, private individuals and business firms make most of the decisions, and the federal and state governments buy needed goods and services predominantly in the private marketplace. US business firms enjoy greater flexibility than their counterparts in Western Europe and Japan in decisions to expand capital plant, to lay off surplus workers, and to develop new products. At the same time, businesses face higher barriers to enter their rivals' home markets than foreign firms face entering US markets.
Long-term problems for the US include stagnation of wages for lower-income families, inadequate investment in deteriorating infrastructure, rapidly rising medical and pension costs of an aging population, energy shortages, and sizable current account and budget deficits.
The onrush of technology has been a driving factor in the gradual development of a "two-tier" labor market in which those at the bottom lack the education and the professional/technical skills of those at the top and, more and more, fail to get comparable pay raises, health insurance coverage, and other benefits. But the globalization of trade, and especially the rise of low-wage producers such as China, has put additional downward pressure on wages and upward pressure on the return to capital. Since 1975, practically all the gains in household income have gone to the top 20% of households. Since 1996, dividends and capital gains have grown faster than wages or any other category of after-tax income.
Imported oil accounts for nearly 55% of US consumption and oil has a major impact on the overall health of the economy. Crude oil prices doubled between 2001 and 2006, the year home prices peaked; higher gasoline prices ate into consumers' budgets and many individuals fell behind in their mortgage payments. Oil prices climbed another 50% between 2006 and 2008, and bank foreclosures more than doubled in the same period. Besides dampening the housing market, soaring oil prices caused a drop in the value of the dollar and a deterioration in the US merchandise trade deficit, which peaked at $840 billion in 2008. Because the US economy is energy-intensive, falling oil prices since 2013 have alleviated many of the problems the earlier increases had created.
The sub-prime mortgage crisis, falling home prices, investment bank failures, tight credit, and the global economic downturn pushed the US into a recession by mid-2008. GDP contracted until the third quarter of 2009, making this the deepest and longest downturn since the Great Depression. To help stabilize financial markets, the US Congress established a $700 billion Troubled Asset Relief Program (TARP) in October 2008. The government used some of these funds to purchase equity in US banks and industrial corporations, much of which had been returned to the government by early 2011. In January 2009, Congress passed and President Barack OBAMA signed a bill providing an additional $787 billion fiscal stimulus to be used over 10 years - two-thirds on additional spending and one-third on tax cuts - to create jobs and to help the economy recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP. In 2012, the Federal Government reduced the growth of spending and the deficit shrank to 7.6% of GDP. US revenues from taxes and other sources are lower, as a percentage of GDP, than those of most other countries.
Wars in Iraq and Afghanistan required major shifts in national resources from civilian to military purposes and contributed to the growth of the budget deficit and public debt. Through 2014, the direct costs of the wars totaled more than $1.5 trillion, according to US Government figures.
In March 2010, President OBAMA signed into law the Patient Protection and Affordable Care Act, a health insurance reform that was designed to extend coverage to an additional 32 million Americans by 2016, through private health insurance for the general population and Medicaid for the impoverished. Total spending on healthcare - public plus private - rose from 9.0% of GDP in 1980 to 17.9% in 2010.
In July 2010, the president signed the DODD-FRANK Wall Street Reform and Consumer Protection Act, a law designed to promote financial stability by protecting consumers from financial abuses, ending taxpayer bailouts of financial firms, dealing with troubled banks that are "too big to fail," and improving accountability and transparency in the financial system - in particular, by requiring certain financial derivatives to be traded in markets that are subject to government regulation and oversight.
In December 2012, the Federal Reserve Board (Fed) announced plans to purchase $85 billion per month of mortgage-backed and Treasury securities in an effort to hold down long-term interest rates, and to keep short-term rates near zero until unemployment dropped below 6.5% or inflation rose above 2.5%. In late 2013, the Fed announced that it would begin scaling back long-term bond purchases to $75 billion per month in January 2014 and further reduce them as conditions warranted; the Fed ended the purchases during the summer of 2014. In 2014, the unemployment rate dropped to 6.2%, and continued to fall to 5.5% by mid-2015, the lowest rate of joblessness since before the global recession began; inflation stood at 1.7%, and public debt as a share of GDP continued to decline, following several years of increases. In December 2015, the Fed raised its target for the benchmark federal funds rate by 0.25%, the first increase since the recession began. With US GDP growth below 2%, the Fed opted to raise rates three times since then, and in mid-June 2017, the range for the target rate stood at 1% to 1.25%.
|
Source
: CIA |
STATUTORY
INFORMATION
|
|
|
|
|
|
Legal Name: |
FLUXION BIOSCIENCES INC. |
|
Trade Names: |
FLUXION BIOSCIENCES INC. |
|
ID: |
4052654 |
|
Date Created: |
2005 |
|
Date
Incorporated: |
10/28/2005 |
|
Legal Address: |
CORPORATION TRUST CENTER 1209 ORANGE ST,
WILMINGTON, NEW CASTLE, DE, 19801, USA |
|
Operative
Address: |
385 Oyster Point Boulevard Suite 3 South San Francisco, CA 94080 United States |
|
Telephone: |
650-241-4777 |
|
Fax: |
650-873-3665 |
|
Legal Form: |
CORPORATION |
|
Email: |
- |
|
Registered in: |
DELAWARE |
|
Website: |
www.fluxionbio.com |
|
Contact: |
Mr. Jeff Jensen - Chief Executive Officer
and Director |
|
Staff: |
30 |
|
Activity: |
SIC Code 3841, Surgical and Medical Instruments
and Apparatus NAICS Code 339112, Surgical and Medical
Instrument Manufacturing |
|
|
|
|
|
|
Banks
|
|
|
BANK OF AMERICA |
|
|
|
|
|
|
|
History
|
|
|
Fluxion Biosciences, Inc. was founded in 2005
and is based in South San Francisco, California. |
|
|
|
|
|
Key
Developmetns: |
Fluxion Biosciences Announces Launch of ERASE-Seq NGS Liquid Biopsy
Analysis Service Jan 4 18 Fluxion Biosciences announced that its ERASE-Seq bioinformatics solution
can now be utilized for variant calling from a wide range of targeted cancer
panels. Until now, ERASE-Seq was limited to use on Fluxion's 59-gene
Spotlight 59 Cancer Panel. ERASE-Seq is now available for use with Swift
Biosciences' Accel Amplicon 56G panel and Illumina's TruSight Tumor 15 panel.
Other custom and commercial panels are also compatible with ERASE-Seq, and
can be added following validation testing by Fluxion. Liquid biopsies offer
the potential to improve treatment of cancer by providing affordable,
non-invasive detection of actionable cancer mutations from a blood sample.
However, the relative abundance of cancer DNA in blood is extremely low,
below the sensitivity threshold of standard sequencers. Approaches such as
molecular barcodes have resulted in improved performance; however, high
sensitivity and, importantly, high specificity have been difficult to achieve
at allele frequencies between 0.1%-0.5%. This is a critical region for
somatic cancer variant detection in liquid biopsies, and ERASE-Seq provides
far superior accuracy here compared to competitive approaches. ERASE-Seq
bioinformatic analyses for the Swift Biosciences 56G and Illumina TruSight
Tumor 15 panels are available immediately via cloud-based analysis. ERASE-Seq
is modular and can be optimized to different sequencing protocols,
sensitivity targets, and input DNA quantities. Fluxion Appoints Genetracer as Certified Service Provider for IsoFlux
CTC Liquid Biopsy System Feb 27 17 Fluxion Biosciences, Inc. has announced the appointment of Genetracer
Biotech as a certified service provider for Fluxion's IsoFlux CTC Liquid
Biopsy System. The IsoFlux system will be used in Genetracer Biotech's novel
liquid biopsy workflows for detection of mutations relevant to lung and colon
cancer, with plans to move to other cancers as additional assays are
developed. The laboratory is utilizing Fluxion's IsoFlux System to isolate,
recover, and analyze CTCs (circulating tumor cells) from routine blood
samples. Liquid biopsies offer the potential to improve treatment of cancer
by providing an affordable, non-invasive diagnostic. Fluxion's technologies
include the IsoFlux system for high-sensitivity detection of cancer cells
from a routine blood draw, and the Spotlight 59 NGS Oncology Panel for
ultra-sensitive mutation detection of CTCs and ctDNA (circulating tumor DNA)
isolated from routine blood samples. These solutions allow testing for a
broad range of cancer biomarkers that will help guide treatment decisions
using an emerging class of precision cancer therapies. As a Certified Service
Provider, Genetracer Biotech will provide liquid biopsy services supporting
cancer research centers and bio-pharmaceutical companies. Additionally,
Genetracer will participate in Fluxion's upcoming liquid biopsy lung cancer
clinical study. The study is aimed at improving lung cancer diagnostics by
providing early stratification of high risk patients. Fluxion Biosciences Introduces Second Generation IonFlux Products Nov 7 16 Fluxion Biosciences has introduced second generation IonFlux automated
patch clamp family products. IonFlux systems will be used by industry and
academic laboratories for ligand and voltage gated ion channel screening.
Developed for ion channel drug discovery, the IonFlux automated patch clamp
system deploys an advanced in-plate cell attachment, recording and drug
delivery system that offers parallel recordings for ligand and voltage-gated
channels. The system also facilitates complicated drug screening assays.
Institutions will use IsoFlux liquid biopsy system and BioFlux cell analysis
system in various disease research areas, including cancer, microbiology, and
immunology. The new product line, which will replace and update the existing
IonFlux product family, will be directly marketed by Fluxion and its
partners. The IonFlux Mercury will substitute the IonFlux 16, while the
IonFlux Mercury HT will replace the IonFlux HT. Earlier, IonFlux systems were
distributed by Molecular Devices. Its in-plate perfusion feature provides
continuous compound flow, helping in assay simplification and speed,
including complicated and long assays. The platform includes new features
such as remote and touch screen experiment execution, highly extended
recording times, new streamlined fluid exchange, standardized temperature
control, and integrated current clamp. |
|
|
|
|
|
|
PRINCIPAL
ACTIVITY
|
|
|
Fluxion Biosciences, Inc. develops
analytical instruments for functional cellular analyses in life science, drug
discovery, and diagnostic applications. |
|
|
|
|
|
Products/Services
description: |
It offers IsoFlux Liquid Biopsy System, a benchtop instrument designed
to enrich rare cell populations, such as circulating tumor cells, cancer stem
cells, rare immunological cells, and more; IsoFlux cell enrichment kits; IsoFlux
downstream analysis kits; BioFlux consumables and accessories for live cell
analysis under shear flow used in the fields of immunology, vascular biology,
microbiology, cancer research, stem cells, and more; and IonFlux systems for
automated patch clamping. The company also provides analytical services for a
range of circulating tumor cell and liquid biopsy applicationsThe company
offers its solutions through a network of distributors in the United States
and internationally. |
|
Brands: |
FLUXION BIOSCIENCES |
|
Sales are: |
Wholesale |
|
Clients: |
It serves biotechnology and pharmaceutical
companies, academic institutions, and government research organizations. |
|
Suppliers: |
NA |
|
Operations area:
|
National and International |
|
The company imports
from |
No import found. |
|
The company
exports to |
No export records found. |
|
The subject
employs |
30 employees |
|
Payments: |
Slow but correct |
|
|
|
|
|
|
LOCATION
|
|
|
Headquarters : |
385 Oyster Point Boulevard Suite 3 South San Francisco, CA 94080 United States |
|
Comments on
Address: |
The address given in the order is the
company´s branch location. |
|
Branches: |
Fluxion Biosciences Inc. (Branch Location) 1600 Harbor Bay Pkwy Alameda, CA, 94502 United States |
|
Related
Companies: |
No related companies were found. |
|
|
|
|
|
|
GROUP STRUCTURE AND SUBSIDIARY COMPANIES
|
|
|
Listed at the
stock exchange: |
NO |
|
Capital: |
NA |
|
Shareholders: |
The
company does not disclose information on shareholders. The following
information has been obtained through private sources and could not be
confirmed: Cristian Ionescu-Zanetti, Ph.D. Michelle Khine, Ph.D. Michael Schwartz |
|
Management: |
Mr. Jeff Jensen - Chief Executive Officer
and Director Ms. Jody Beecher Ph.D. - Vice President of
Operations Mr. Cristian Ionescu-Zanetti Ph.D. - Chief
Technology Officer Mr. Ali Yehia Ph.D. - Vice President of
Electrophysiology & Drug Screening Mr. Bryan Haines Ph.D. - Global Director
of Bioflux Sales and Support |
|
|
|
|
|
|
FINANCIAL
INFORMATION
|
|
|
|
|
|
The company does not make its financial statements public. The
following information has been provided by private sources: |
|
|
|
|
|
USD 2015 |
|
|
Revenue |
3.820.000 |
|
Cash flow |
Normal |
|
|
|
|
|
|
LEGAL
FILINGS
|
|
|
|
|
|
PATENTS |
METHODS AND APPARATUS FOR THE MANIPULATION OF PARTICLE SUSPENSIONS AND
TESTING THEREOF Publication number: 20120264134 Abstract: Apparatus and methods are provided for analysis of
individual particles in a microfluidic device. The methods involve the
immobilization of an array of particles in suspension and the application of
experimental compounds. Such methods can also include electrophysiology
studies including patch clamp recording, electroporation, or both in the same
microfluidic device. The apparatus provided includes a microfluidic device
coupled to a multi-well structure and an interface for controlling the flow of
media within the microchannel device. Type: Application Filed: April 24, 2012 Publication date: October 18, 2012 Applicant: Fluxion Biosciences Inc. Inventors: Cristian Ionescu-Zanetti, Michelle Khine, Michael Schwartz DEVICES, SYSTEMS, AND METHODS FOR MAGNETIC SEPARATION Publication number: 20130017538 Abstract: Methods, microfluidic devices, and instruments for magnetic
separation of particles from a fluid are described. Examples include
microfluidic devices having a removable portion. Examples include microfluidic
devices having one or more regions of reduced fluid velocity. Examples
further including instruments having pneumatic interfaces. Examples further
includes instruments having controllable magnets, imaging components, or
combinations thereof. Type: Application Filed: July 14, 2011 Publication date: January 17, 2013 Applicant: Fluxion Biosciences Inc. Inventors: Cristian Ionescu-Zanetti, Joshua Tanner Nevill, Michael
Schwartz, Carolyn G. Conant, Roger Rudoff Methods and apparatus for the manipulation of particle suspensions and
testing thereof Patent number: 8293524 Abstract: Apparatus and methods are provided for analysis of
individual particles in a microfluidic device. The methods involve the
immobilization of an array of particles in suspension and the application of
experimental compounds. Such methods can also include electrophysiology
studies including patch clamp recording, electroporation, or both in the same
microfluidic device. The apparatus provided includes a microfluidic device
coupled to a multi-well structure and an interface for controlling the flow
of media within the microchannel device. Type: Grant Filed: March 25, 2007 Date of Patent: October 23, 2012 Assignee: Fluxion Biosciences Inc. Inventors: Cristian Ionescu-Zanetti, Michelle Khine, Michael Schwartz,
Andrew Blatz |
|
|
|
|
GOVERNMENT
CONTRACTS |
Name & Address: FLUXION BIOSCIENCES
INC. 385 OYSTER POINT BLVD STE 3 SOUTH SAN FRANCISCO, CA 94080-1934 Number of Defense Contracts Awarded:11 Dollar Amount of Defense Contracts Awarded:
$370,607 |
|
|
|
|
CASES |
Cellectricon AB v. Fluxion Biosciences,
Inc. Plaintiff: Cellectricon AB Defendant: Fluxion Biosciences, Inc. Case Number: 5:2011cv03009 Filed: June 17, 2011 Court: California Northern District Court Office: San Jose Office County: San Francisco Presiding Judge: Ronald M. Whyte Nature of Suit: Patent Cause of Action: 35:271 Jury Demanded By: Plaintiff Cellectricon AB v. Fluxion Biosciences,
Inc. Plaintiff: Cellectricon AB Defendant: Fluxion Biosciences, Inc. Case Number: 3:2011cv03009 Filed: June 17, 2011 Court: California Northern District Court Office: San Francisco Office County: San Francisco Presiding Judge: Elizabeth D. Laporte Nature of Suit: Patent Cause of Action: 35:271 Jury Demanded By: Plaintiff Cellectricon AB et al v. Fluxion
Biosciences, Inc. Plaintiff: Cellectricon AB and Gyros AB Defendant: Fluxion Biosciences, Inc. Case Number: 5:2009cv03150 Filed: July 10, 2009 Court: California Northern District Court Office: San Jose Office County: XX US, Outside State Presiding Judge: Ronald M. Whyte Nature of Suit: Plaintiff Cause of Action: 35:271 Patent
Infringement Jury Demanded By: Plaintiff |
|
|
|
|
TRADEMARKS |
No records found. |
|
|
|
|
RENEWAL HISTORY |
No records found. |
|
|
|
|
UCC |
No records found. |
|
|
|
|
OFAC Sanctions List
Search |
The company is not listed in the OFAC
list. |
|
|
|
SUMMARY
|
|
|
Founded in 2005, Fluxion Biosciences is an
organization in the Surgical and Medical Instrument Manufacturing Industry
headquartered in San Francisco, California. The company has 30 regular employees and
generates an estimated $3.8 million USD in annual revenue. The company operates nationally and
internationally. It is ACTIVE in business with a medium credit risk. |
|
|
|
|
|
|
|
RISK
INFORMATION
|
|
|
|
|
|
DEBTS |
Controlled |
|
PAYMENTS |
Slow but correct |
|
CASH
FLOW |
Normal |
|
STATUS |
Active |
|
|
|
|
INTERVIEW |
|
|
NAME |
Ashley |
|
POSITION |
Operations |
|
COMMENTS |
She confirmed the name of the company, the
address of the headquarters and location, the date of creation of the
company, the number of employees and the name of the Chief Executive Officer. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 63.72 |
|
|
1 |
INR 88.64 |
|
Euro |
1 |
INR 78.14 |
|
USD |
1 |
INR 63.83 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
VAR |
|
|
|
|
Report Prepared
by : |
SYL |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.